Home › Companies › SRPT

Sarepta Therapeutics

Market cap $1.58B 107.2M shares (10-Q, Nov 2, 2026) × $14.77 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Catalent clean room agreement corporate4Q 2026Catalent clean room agreement corporate, 4Q 2026, routine
  2. ELEVIDYS readout1Q 2027ELEVIDYS readout, 1Q 2027, major
  3. ELEVIDYS ENDEAVOR readout1Q 2027ELEVIDYS ENDEAVOR readout, 1Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (11 active programs)

Technology platforms

AAVrh74

Adeno-associated virus vector platform using the AAVrh.74 serotype to deliver gene therapy transgenes to target muscle cells; used for Duchenne muscular dystrophy (ELEVIDYS/SRP-9001) and limb-girdle muscular dystrophy programs (SRP-9003). Platform technology designation previously granted by FDA in June 2025, subsequently revoked.

Targets: dystrophin, beta-sarcoglycan

αvβ6 integrin-targeted delivery platform

siRNA delivery platform utilizing αvβ6 integrin targeting for muscle diseases, including facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1)

Targets: αvβ6 integrin

Discontinued (3)

Capital (as filed)

Cash
$473M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$406M Sep 30, 2026
Long-term investments
$109M Sep 30, 2026
Operating cash flow
$60.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$999M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Sarepta Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Sarepta Therapeutics (SRPT): Scientific Deep Dive for Lead and Pipeline Products ELEVIDYS has durable 3-year efficacy data and a $1.86B revenue floor; accumulate slowly ahead of the 2H 2026 Cohort 8 readout while managing AAV toxicity risk.
  2. Hold UPDATE: Sarepta (SRPT) - The Captain Bails Before the Storm? Abrupt CEO departure introduces acute execution risk; hold existing positions but keep powder dry until the 1,200-patient safety data at the MDA Congress in March.
  3. Hold UPDATE: Sarepta Therapeutics (SRPT) - The Other Shoe Drops The 10-K reveals $165M in AAV manufacturing write-offs and an $884M Arrowhead charge; maintain hold while watching Q1 siRNA data and the MDA Congress safety presentation.
  4. Hold UPDATE: Sarepta Therapeutics (SRPT) - Fortifying the Shield and Unsheathing the Sword PMO full-approval submissions and Cohort 8 enrollment initiation are stabilizing moves, but the $165M manufacturing write-off overhang warrants waiting to add until Q3/Q4 Cohort 8 liver toxicity data.
  5. Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - Unsheathing the Sword First clinical siRNA data validates the $883M Arrowhead investment; the thesis is de-risking with a cash-flowing PMO Shield, Cohort 8 wildcard, and newly validated siRNA platform making $19.97 an attractive speculative entry.
  6. Hold UPDATE: Sarepta Therapeutics (SRPT) - The 10-K Mea Culpa Three of four original buy assumptions broke (ESSENCE failed, platform designation revoked, LGMD on clinical hold); the free pipeline option is gone and the risk/reward has shifted to a binary-event hold pending Cohort 8.
  7. Hold UPDATE: Sarepta Therapeutics (SRPT) - The Headline Beat That Wasn't Q1 ELEVIDYS revenue collapsed 73% YoY to $102M; the headline GAAP profit is an accounting artifact, and the thesis is now a single-event hold on Cohort 8 data in late Q4 2026/Q1 2027.
  8. Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The FDA Took the Meeting FDA accepting the PMO sNDAs modestly de-risks the Shield, but the dominant variable remains Cohort 8 sirolimus data; at $17.97 the stock is closer to fair value for a binary-hold but not yet a compelling entry.
  9. Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Chair Gets Filled Hiring development-focused CEO Severino retires the leadership-vacuum risk premium but cannot change Cohort 8 outcomes; the binary is still measured in sirolimus weeks and liver enzymes, not résumés.
  10. Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Clock Slips a Quarter Cash stabilized with a $197M build and operating burn nearly zero, but Cohort 8 full enrollment slipped to year-end 2026 with 12-week data now formally in Q1 2027, extending the hold by a quarter.
  11. Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Calendar Gets a Date PMO PDUFA date set for Feb 28 2027 and cash near $1B are positives, but ELEVIDYS broke below the $400M annualized floor and the Catalent charge confirms AAV franchise shrinkage; the thesis now rests on the Q1 2027 MAD/PDUFA/Cohort 8 catalyst stack.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

15 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)